The study of ANCA for efficacy of biologics therapy in patients with ulcerative colitis

Not Applicable

Recruiting

• Conditions: lcerative colitis

• Registration Number: JPRN-UMIN000043883
• Lead Sponsor: Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-10
• Last Update Posted: 17 October 2023
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Persons who did not obtain consent after the explanation (2) Those who cannot get an understanding by explaining it verbally (3) Persons who have already been administered biopharmacy at the time of obtaining consent (4) Partial Mayo score 2 points or less

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome of this study is proportion of patients with primary non-response to biologics stratified by PR3-ANCA and MPO-ANCA positivity.

Secondary Outcome Measures

Name	Time	Method
The secondary outcome of this study is proportion of patients with loss of response to biologics stratified by PR3-ANCA and MPO-ANCA positivity.